伏美替尼联合全脑放疗治疗非小细胞肺癌脑转移患者的临床效果
Clinical effect of furmonertinib combined with whole brain radiotherapy in the treatment of non-small cell lung cancer patients with brain metastases
袁燕 1梁博 2肖正红2
作者信息
- 1. 南阳南石医院 放疗科,河南 南阳 473000
- 2. 南阳南石医院 肿瘤科,河南 南阳 473000
- 折叠
摘要
目的 探讨伏美替尼联合全脑放疗治疗非小细胞肺癌(NSCLC)脑转移患者的临床效果.方法 将90例NSCLC脑转移患者根据治疗方案的不同分为对照组47例和研究组43例.对照组患者采取吉非替尼联合全脑放疗,研究组患者采取伏美替尼联合全脑放疗.比较两组患者的临床疗效、肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]、不良反应发生情况以及生活质量[肺癌患者生命质量测定量表(FACT-L)].结果 研究组患者疾病控制率高于对照组,差异有统计学意义(P﹤0.05).治疗后,两组患者CYFRA21-1、CA19-9、CEA水平均较治疗前降低,且研究组患者CYFRA21-1、CA19-9、CEA水平均低于对照组,差异均有统计学意义(P﹤0.05).治疗后,两组患者FACT-L各维度评分均较治疗前升高,且研究组患者FACT-L各维度评分均高于对照组,差异均有统计学意义(P﹤0.05).两组患者不良反应总发生率比较,差异无统计学意义(P﹥0.05).结论 伏美替尼联合全脑放疗治疗NSCLC脑转移患者有一定的疗效,可降低肿瘤标志物水平,提高患者生活质量,且具有一定的安全性.
Abstract
Objective To investigate the clinical effect of furmonertinib combined with whole brain radiotherapy in the treatment of non-small cell lung cancer(NSCLC)patients with brain metastases.Method A total of 90 NSCLC pa-tients with brain metastases were divided into control group(47 cases)and study group(43 cases)according to different treatment regimens.The control group received gefitinib combined with whole brain radiotherapy,and the study group re-ceived furmonertinib combined with whole brain radiotherapy.The clinical efficacy,tumor markers[cyto-keratin 19 frag-ment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)],incidence of adverse reactions and quality of life[functional assessment of cancer therapy-lung(FACT-L)]were compared between the two groups.Result The disease control rate of the study group was higher than that of the control group,and the dif-ference was statistically significant(P<0.05).After treatment,the levels of CYFRA21-1,CA19-9 and CEA in two groups were lower than those before treatment,and the levels of CYFRA21-1,CA19-9 and CEA in study group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,the scores of all dimensions of FACT-L in the two groups were higher than those before treatment,and the scores of all dimensions of FACT-L in the study group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Fur-monertinib combined with whole brain radiotherapy is effective in the treatment of NSCLC patients with brain metasta-ses,can reduce the level of tumor markers,improve the quality of life,and has a certain safety.
关键词
肺癌/脑转移/伏美替尼/全脑放疗Key words
lung cancer/brain metastases/furmonertinib/whole brain radiotherapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据